I view this amfAR PR quite favorably. These types of indication-specific cooperative agreements will jump-start progress, while providing very good investor optics.

What I don't quite understand is why Dr. Hope Rugo has not been able to contribute a single mTNBC patient to our trial. I realize that's not specifically her job, but I would have thought she'd have a number of patients who could benefit.